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Abstract
Background: Patient age is one of the most salient clinical indicators of risk from COVID-19. Age-specific distributions
of known SARS-CoV-2 infections and COVID-19-related deaths are available for many regions. Less attention has been
given to the age distributions of serious medical interventions administered to COVID-19 patients, which could reveal
sources of potential pressure on the healthcare system should SARS-CoV-2 prevalence increase, and could inform
mass vaccination strategies. The aim of this study is to quantify the relationship between COVID-19 patient age and
serious outcomes of the disease, beyond fatalities alone.
Methods: We analysed 277,555 known SARS-CoV-2 infection records for Ontario, Canada, from 23 January 2020 to 16
February 2021 and estimated the age distributions of hospitalizations, Intensive Care Unit admissions, intubations, and
ventilations. We quantified the probability of hospitalization given known SARS-CoV-2 infection, and of survival given
COVID-19-related hospitalization.
Results: The distribution of hospitalizations peaks with a wide plateau covering ages 60–90, whereas deaths are
concentrated in ages 80+. The estimated probability of hospitalization given known infection reaches a maximum of
27.8% at age 80 (95% CI 26.0%–29.7%). The probability of survival given hospitalization is nearly 100% for adults
younger than 40, but declines substantially after this age; for example, a hospitalized 54-year-old patient has a 91.7%
chance of surviving COVID-19 (95% CI 88.3%–94.4%).
Conclusions: Our study demonstrates a significant need for hospitalization in middle-aged individuals and young
seniors. This need is not captured by the distribution of deaths, which is heavily concentrated in very old ages. The
probability of survival given hospitalization for COVID-19 is lower than is generally perceived for patients over 40. If
acute care capacity is exceeded due to an increase in COVID-19 prevalence, the distribution of deaths could expand
toward younger ages. These results suggest that vaccine programs should aim to prevent infection not only in old
seniors, but also in young seniors and middle-aged individuals, to protect them from serious illness and to limit stress
on the healthcare system.
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Background
In early 2020, the first outbreak of severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) was reported
in Wuhan, Hubei Province, China [1]. The virus, which
can cause the development of Coronavirus Disease 2019
(COVID-19), has been detected in 223 of the 237 coun-
tries, territories, and areas recognized by the World
Health Organization [2]. Different regions have seen vary-
ing degrees of success with their specific mitigation strate-
gies. Notably successful countries include Vietnam [3–5],
New Zealand [6, 7], and Taiwan [8–10], which serve as
important case studies for future pandemic preparedness
efforts.
Other countries, including Canada, initially succeeded
in controlling the spread of the virus, but went on to suf-
fer a large second wave of infection amid reopening efforts
[11, 12]. Even within Canada, COVID-19 mitigation suc-
cess has varied by region. The Atlantic provinces of New
Brunswick, Nova Scotia, and Prince Edward Island have
been successful in controlling SARS-CoV-2 spread, with
only small, occasional outbreaks that were rapidly con-
tained [11, 13]. Other, larger, provinces, especially Ontario
and Quebec, have struggled with critical periods of large
and/or rapidly increasing known infection (KI) counts,
responding with strict measures such as stay-at-home
orders [14–16] and curfews [17].
Our study is based on SARS-CoV-2 KI records in
Ontario, where the first reported infection of SARS-CoV-
2 was confirmed on 23 January 2020. The virus was
detected sporadically in the province through February
2020 [18], until the number of KIs began to rise consis-
tently in March 2020. Ontario declared its first pandemic-
related state of emergency on 17 March 2020 [19], imple-
menting a large-scale economic shutdown and school clo-
sures to mitigate spread of the virus. The province began
reopening in stages through the summer [20] amid rel-
atively low SARS-CoV-2 infection prevalence, with most
schools reopening early-to-mid September [21]. In late
September, additional restrictions were enacted across the
province in response to the beginning of a second wave
of infection [22–24], and on 23 November 2020 a lock-
down was enacted in the heavily populated Toronto and
Peel regions [25]. A province-wide shutdown began on
26 December 2020 [26], with an even stricter provincial
stay-at-home order coming into effect on 14 January 2021,
after KIs doubled in the preceding two weeks [27, 28].
The regions of Toronto, Peel, and North Bay-Parry Sound
remain under this stay-at-home order as of 1 March 2021
[15], while the rest of the province follows a new zoned
reopening framework [16]. Figure 1 summarises the time
course of the SARS-CoV-2 epidemic in Ontario, as repre-
sented by KIs up to 16 February 2021.
One of the main motivations behind ongoing SARS-
CoV-2 infection control efforts, in Ontario and around
the world, is to ensure that hospitals do not become over-
whelmed with a large demand for COVID-19 treatment.
As well as compromising care of COVID-19 patients,
a large demand for COVID-19 treatment would reduce
access to and quality of care for many other condi-
tions. With COVID-19 vaccination campaigns beginning
around the world, policy-makers must seek to optimize
vaccine distribution given limited supply. To protect indi-
viduals as well as the healthcare system, it is important
to identify groups that are most likely to require signifi-
cant medical care. Severity of COVID-19 presentation is
highly variable among individuals, but increases with age
[29–32]. Deaths attributed to COVID-19 have been found
to be strongly concentrated in the elderly [33–35]. Com-
paratively few studies have explored the age distribution of
serious medical interventions administered to COVID-19
patients [36, 37].
Methods
The goal of this study is to quantify the relationships
between COVID-19 patient age and the administration of
serious medical interventions (hospitalizations, intensive
care unit (ICU) admissions, intubations, and ventilations)
for the province of Ontario. We compare these age-
intervention associations with the age distributions of KIs
and deaths. We also estimate the age-specific probabil-
ity of hospitalization given known SARS-CoV-2 infection,
and of survival given hospitalization related to COVID-19,
to provide measures of individual risk.
Data
We use individual-level records (line lists) for SARS-
CoV-2 KIs reported from 23 January 2020 (the date
of the first infection confirmation in Ontario) up to
16 February 2021 from the Case and Contact Man-
agement (CCM) database maintained by Public Health
Ontario. This confidential central database includes
detailed records of SARS-CoV-2 infections across the
entire province of Ontario. These records include an
individual’s demographic information (such as age),
whether COVID-19-related interventions (including hos-
pitalization, ICU admission, intubation, ventilation) were
administered, as well as whether the infection was
fatal.
The CCM database includes 288,532 KI records up to
16 February 2021. However, we analyse only KIs marked
as “resolved” or “fatal” (N = 277, 555) to avoid tally-
ing patients whose final outcomes are not yet known.
KIs are marked as “resolved” in CCM based on public
health unit assessment. In all instances, a record is con-
sidered resolved if it is 14 days past the symptom onset
date (or specimen collection if symptom onset date is not
known), though public health occasionally performs addi-
tional follow-up to update records. For brevity, we use
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Fig. 1 Known infections (KIs) over time in Ontario. Counts are split by whether or not the KI was resolved (marked as “resolved” or “fatal” in the Case
and Contact Management database) by 16 February 2021 (see “Methods” section). Dashed vertical lines mark important dates for the outbreak in
the province. Shaded regions indicate roughly when the most populous regions were in each reopening stage (reopening efforts have not been
uniform across public health units). Larger stage numbers correspond to looser public health restrictions. Detailed descriptions of each reopening
stage, recent shutdowns, and the newer zoned reopening framework can be found on the official Ontario COVID-19 website [16, 20, 25–28]
“resolved KIs” in our analysis to refer to KIs marked as
either “resolved” or “fatal” in CCM.
For population counts, we use 2020 Ontario population
projections produced by Statistics Canada [38], specifi-
cally projections from the “M1” medium-growth scenario
[39]. (All scenarios yield virtually identical projections for
the short time horizon considered in this paper.)
We use provincial SARS-CoV-2 testing data from
the Ontario Laboratories Information System (OLIS)
database. This database records all tests for active SARS-
CoV-2 infection performed through the provincial health
system. These data are based on reports up to 16 Febru-
ary 2021 and include 270,402 positive tests and 9,163,489
negative tests.
We aggregate counts of all age-specific data (KIs, popu-
lation, and tests) into two-year age bins, with one wide bin
for individuals over 100 years old.
Statistical models for probability estimates
To estimate the age-specific probabilities of hospitaliza-
tion given KI, and of survival given hospitalization, we
use two different approaches. In each case, we estimate
a conditional probability of outcome X given that out-
come Y has occurred and quantify uncertainty around this
estimate using 95% confidence intervals.
The first approach is to consider each age group inde-
pendently, and to assume that the number of times event
X has occurred (given Y ) follows a binomial distribution.
We use the maximum likelihood estimate of the probabil-
ity of outcome X given Y, which is simply the proportion
of instances of Y where X has also occurred (points in
Fig. 4).We then quantify the uncertainty around this point
estimate by constructing a 95% Clopper-Pearson (exact)
confidence interval (vertical bars in Fig. 4).
The second approach involves making the stronger
assumption that there is a smooth relationship between
age and the focal probability (curves in Fig. 4). We use
a binomial generalized linear model (GLM) to estimate
the age-specific survival probability given hospitalization
[40]. This model assumes that probabilities follow a logis-
tic curve as a function of age, and appears to be sufficient
to quantify the monotonic relationship between survival
probability and age. For the probability of hospitalization
given KI, we use a binomial generalized additive model
(GAM) [41], a generalization of the GLM that allows for
non-monotonic trends. In particular, we fit a piecewise
cubic spline (a penalized regression spline) to the log-odds
as a function of age. Both of these parametric models give
more precise results, and narrower confidence intervals
(shaded bands in Fig. 4), than we obtain by computing
probabilities and exact confidence intervals (age-by-age).
Results
Figure 2 shows the age structure of resolved KIs, pop-
ulation demographics, and SARS-CoV-2 infection tests.
The pattern observed in the raw counts of resolved KIs
(panel a) reflects underlying demographics (panel b) as
well as the testing intensity (panel d). Testing intensity,
defined as the number of tests administered per 10,000
population by age group, increases sharply after age 75.
The test positivity rate (panel e), defined as the propor-
tion of tests administered that were positive, also reveals
heterogeneities in testing across age groups, peaking in
14–15-year-olds. Controlling for demography, the num-
ber of detected infections (panel c) is comparatively low
in ages under 15, increases to a plateau for ages 20–70
(with a noticeable peak around age 25), and then contin-
ually increases after age 70. The number of resolved KIs
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Fig. 2 Age distribution of known infections (KIs) in Ontario. The distribution of ages for resolved KIs (panel a), Ontario population projections for
2020 (panel b), resolved KIs per 10,000 population (panel c), positive and total SARS-CoV-2 infection tests per 10,000 population (panel d), and test
positivity rate (panel e). The test positivity rate is the proportion of tests administered that were positive. The y-axes in panels c and d are on a
logarithmic scale
per capita is 1.43 times higher in ages 20–29 than in ages
30–69.
Figure 3 shows the distribution of ages for serious med-
ical interventions (panel a) and deaths (panel b) related
to COVID-19 for resolved KIs. We present raw counts,
as opposed to counts normalized by the age-specific pop-
ulation, because the raw counts (not per capita counts)
determine the pressure on the healthcare system. Hospi-
talizations are split by the most intensive known inter-
vention (with ventilator use being the most intensive,
followed by intubation, then ICU admission, then hospi-
talization). Deaths are split by whether or not the patient
has a record of hospitalization for COVID-19 treatment.
The distribution of serious medical interventions is
much wider than that of deaths, with the latter peaking
at age 90. Hospitalizations are relatively uniformly spread
between ages 60–90, while the distribution of ICU-related
interventions (ICU admission, intubation, ventilation) is
spread over a slightly younger age range. The total num-
ber of COVID-19 deaths in Ontario up to 16 February
2021 was 6,728, of which 3,475 (51.6%) had no record of
hospitalization for treatment related to COVID-19.
Figure 4 shows the estimated hospitalization probability
given known SARS-CoV-2 infection (panel a) and survival
probability given hospitalization for COVID-19 treatment
(panel b). These metrics quantify individual risk of serious
COVID-19 outcomes as a function of age (without expli-
citly controlling for other factors like comorbidities; see
“Limitations” section). The large uncertainty in age-by-
age probability estimates for some young and very old age
groups is due to small numbers of KIs and hospitalizations
in these ages. However, the estimated uncertainty is much
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lower with the model-based approach (see Methods:
“Statistical models for probability estimates” section).
Based on age-by-age estimates, the hospitalization prob-
ability peaks in the 80–81 age group at 27.8% (95% CI
26.0%–29.7%). In adults, the survival probability is near
100% until about age 40, where it begins to decline
steadily. For instance, a hospitalized individual in the age
group 54–55 has a 91.7% chance of surviving COVID-19
(95%CI 88.3%–94.4%; according to age-by-age-estimates),
implying that nearly 1 in 12 hospitalized COVID-19
patients in this age group die despite receiving acute care
for the illness.
Discussion
The age distributions of known SARS-CoV-2 infections
(Fig. 2a) and deaths attributed to COVID-19 (Fig. 3b)
on their own provide limited insight into the risk that
COVID-19 patients could overwhelm Ontario’s health-
care system. The majority of COVID-19-related deaths
have occurred in patients with no record of hospitaliza-
tion (Fig. 3b). Many deaths have occurred in long-term
care (LTC) facilities, which are independent of the hos-
pital system [42], and have experienced significant out-
breaks [42, 43] (Fig. 2c), necessitating considerable disease
surveillance in very old age groups (Fig. 2d). (These LTC
deaths may partially explain the observed decrease in the
hospitalization probability after age 80, Fig. 4a.) Unlike
the distribution of deaths (Fig. 3b), the broad age distribu-
tions of hospitalizations, ICU admissions, intubation, and
ventilation (Fig. 3a) reveal the potential pressure on the
healthcare system from both middle-aged individuals and
seniors.
Early in the outbreak, the province of Ontario expanded
coverage for COVID-19-related treatment to include even
individuals who are not usually covered by the Ontario
Health Insurance Plan [44]. Access to prompt and success-
ful medical interventionsmay have kept a large proportion
of COVID-19-related hospitalizations from resulting in
deaths. While we expect that the shape of the age dis-
tribution of the need for hospitalization (Fig. 3a) would
remain the same if prevalence were to increase signifi-
cantly, the distribution of deaths (Fig. 3b) may expand
toward younger ages if hospitals and ICUs reach maxi-
mum capacity (due to an insufficient supply of acute
care).
This potential need for acute care, coupled with elevated
individual risks associated with COVID-19 in the same
age range (Fig. 4), support the prioritization of infection
prevention in young seniors and middle-aged individuals
(in addition to old seniors) when designing vaccine distri-
bution strategies. However, this result does not necessarily
imply that an age-based “oldest-to-youngest” vaccination
strategy is optimal to achieve the goal of preventing infec-
tion in these groups. A recent study by Mulberry et al.
[45] suggests that overall vaccination strategies prioritiz-
ing essential workers can indirectly protect the most vul-
nerable groups and outperform oldest-to-youngest vacci-
nation strategies by reducing the number of KIs, hospi-
talizations, deaths, instances of “long COVID” [46], and
by increasing net economic benefit. Vaccination strate-
gies targeting groups most likely to transmit the disease
(with the goal of protecting vulnerable groups) have been
explored previously in the context of seasonal influenza
[47]. For COVID-19, strategies prioritizing groups most
Fig. 3 COVID-19 outcomes by age in Ontario. The distribution of ages for hospital interventions (panel a), and deaths (panel b). Hospital outcomes
are nested and tallied by the most intensive medical intervention used for each patient (ventilator use is the most intensive, followed by intubation,
ICU admission, and hospitalization). Deaths are split by whether or not the patient also had a record of hospitalization for COVID-19 treatment
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Fig. 4 Age-dependent COVID-19 hospitalization probability for known SARS-CoV-2 infection (panel a) and survival probability for hospitalized
patients (panel b) in Ontario. We give age-by-age estimates of each probability (points; 95% exact binomial confidence intervals given by vertical
lines), where point area is proportional to age-specific sample size. We additionally provide more precise estimates of these probabilities under
stricter assumptions, modelling the hospitalization probability using a generalized additive model and the survival probability using a generalized
linear model (curves; 95% confidence bands given by shaded regions). See “Methods” section for details
likely to transmit the virus are especially effective when
the vaccine has high efficacy (in terms of reducing suscep-
tibility to infection) [48], which is true of several leading
COVID-19 vaccines [49–52].
The age-dependent probabilities of hospitalization
given KI (Fig. 4a) are based on resolved known infections,
and so they depend on how widely SARS-CoV-2 testing
has been conducted. Throughout the period covering a
large portion of the CCM data, testing guidelines selected
for sufficiently symptomatic individuals [53]. These guide-
lines were not expanded to include asymptomatic individ-
uals from the general public until 29 May 2020 [54] and
were rolled back on 24 September 2020 in an effort to pre-
serve limited testing resources amid a surge in KIs [55]. As
a result, untargeted asymptomatic testing was offered only
in the summer, when prevalence was relatively low, which
represents a small proportion of the data. Moreover, indi-
viduals may not be prompted to get tested in the absence
of symptoms unless they are included in a contact tracing
investigation. The probability of hospitalization given KI
therefore likely overestimates the underlying probability
of hospitalization given infection, whether known or not.
Our survival probability estimates for hospitalized indi-
viduals (Fig. 4b) are not affected by the same detection
biases present in KI data. Patients admitted to hospital
are tested for SARS-CoV-2 as part of infection control
protocols, and thus infection detection in hospitalized
individuals is not influenced by testing guidelines for the
general population. Our survival probability estimates do,
however, represent an upper bound with respect to the
current standard of care and viral variant. In the absence
of significant innovation in COVID-19 treatment or viral
evolution to lower disease severity, we expect survival
probabilities would decrease if ICUs or hospitals were to
reach maximum capacity.
Limitations
Age is a simple and accessible proxy for risk factors,
including existing comorbidities that may affect COVID-
19 outcomes, which on average scale with age. This study
did not explicitly account for comorbidities and other fac-
tors that could correlate with the severity of COVID-19
outcomes.
In general, KIs underestimate the true prevalence of
SARS-CoV-2 infection for a variety of reasons, including
test availability, ease of testing, test accuracy, and difficul-
ties in detecting asymptomatic individuals. The majority
of KIs captured in the data analysed in this study occurred
when testing guidelines were selecting for sufficiently
symptomatic individuals, and so asymptomatic and mild
infections are likely underrepresented.
This study is specific to the Ontario SARS-CoV-2 epi-
demic, though the results have implications for COVID-
19 outbreaks all over the world. Contact patterns in
Ontario have changed over the course of the pandemic
due to the province’s continuing effort to control COVID-
19 spread while also supporting the economy. Observed
patterns in the age distributions of KIs and deaths may
change as the age-specific contact structure and contact
rates continue to change.
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Conclusions
We have quantified the age distributions of serious med-
ical interventions for SARS-CoV-2 infection in Ontario,
Canada, for the entire period of the regional epidemic
through 16 February 2021. Our results reveal a large need
for hospitalization in a broad age range (mainly ages 60-
90): a threat of the ongoing COVID-19 pandemic that is
not revealed by the age distribution of KIs and deaths
alone. If healthcare capacities were to be exceeded due to
an increase in prevalence, the need for COVID-19-related
acute caremay not bemet adequately, which could expand
the existing distribution of deaths toward younger ages.
Moreover, the probability of survival given COVID-19-
related hospitalization is lower than is generally perceived
for patients over 40. Vaccination programs prioritizing
older age groups to prevent deaths should consider broad-
ening their priorities to also prevent infection in younger
seniors and middle-aged individuals, in order to help
ensure the healthcare system does not exceed its capacity
for acute care.
TheGovernment of Canada and the Province of Ontario
have implemented policies meant to help mitigate SARS-
CoV-2 spread while also undertaking a phased reopening
[16, 20, 56]. Future work should consider whether the age
dependence of SARS-CoV-2 infection risks is changing
over time, as the population continues to navigate the pan-
demic and the testing effort expands. Our study explores
only short-term SARS-CoV-2 infection outcomes; future
studies should explore the age distributions of long-term
morbidities from this infection, so that we may bet-
ter understand the heterogeneous risks associated with
COVID-19. Lastly, all studies relying on KI counts are sub-
ject to bias from how infections are detected via active
infection testing. Future work should seek to correct for
this bias.
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